At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 32 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
In Brief
A Phase 3 clinical trial evaluating Ketamine and Normal saline for Postoperative Depression. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This protocol describes a feasibility trial that will evaluate the feasibility of conducting a full-scale phase 3 trial testing the hypothesis that a postoperative sustained, low-dose ketamine infusion can prevent postoperative depressive symptoms when administered to a targeted population of neurosurgical patients with a history of depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Depression
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartApr 2022
Primary CompletionMar 2023
TodayJul 2026
First PostedFeb 10, 2022
Enrollment StartApr 25, 2022
Primary CompletionMar 8, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.4 years ago
Interventions
Ketaminedrug
NMDA antagonist
Normal salinedrug
IV fluid acting as a placebo